Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7389179 | 0.88 | TNKS (0.33) | — | |
| SCHEMBL8491759 | 0.79 | SMN1; SMN2 (0.33) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13176522 | 0.79 | SMN1; SMN2 (0.34) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL23084550 | 0.71 | NPC1 (0.30) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL14095085 | 0.70 | MEN1 (0.38) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL12312857 | 0.69 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTALDH1A1POLBKMT2A | |
| SCHEMBL9384614 | 0.68 | TNKS (0.31) | — | |
| SCHEMBL11035315 | 0.68 | KDM4E (0.35) | MAPTALDH1A1L3MBTL1KDM4E | |
| SCHEMBL23068559 | 0.68 | — | — | |
| SCHEMBL30712008 | 0.67 | SMN1; SMN2 (0.38) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640095-A | Diaryl amine derivative containing aliphatic carboxyl and preparation method and application thereof | 山东大学 | 2023-08-25 | — | — | CN | claimed |
| EP-4678644-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yidi Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4674852-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | Innovstone Therapeutics Limited (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20250263426-A1 | PDE4B INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| CN-116444497-B | Pyridazinone compound, preparation and application thereof | 如东凌达生物医药科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025124557-A1 | DEUTERATED HETEROCYCLIC COMPOUND ACTING AS PDE4B INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4570804-A1 | PDE4B INHIBITOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-120157682-A | Deuterated heterocyclic compounds as PDE4B inhibitors and uses thereof | 武汉人福创新药物研发中心有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006111549-A1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | NPC1 1758/4885RAB9A 2480/4885SMN1; SMN2 2728/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | NPC1 746/4885RAB9A 1370/4885SMN1; SMN2 1774/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | NPC1 4397/4885RAB9A 2130/4885SMN1; SMN2 1736/4885 |
| US-20250263426-A1 | PDE4B INHIBITOR AND USE THEREOF | PDE4B, PDE4A, PDE3B | NPC1 2175/4885RAB9A 668/4885SMN1; SMN2 1237/4885 |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | DPYD, DHODH, DPM1 | NPC1 1909/4885RAB9A 1497/4885SMN1; SMN2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.